Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

@article{Weller2017RindopepimutWT,
  title={Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.},
  author={Michael Weller and Nicholas A. Butowski and David Dinh Tran and Lawrence Recht and Michael Lim and Hal W. Hirte and Lynn S. Ashby and Laszlo L. Mechtler and Samuel A. Goldlust and Fabio M. Iwamoto and Jan Drappatz and Donald M. O'Rourke and Mark Yu Zheng Wong and Mark G. Hamilton and Gaetano Finocchiaro and James A Perry and Wolfgang Wick and Jennifer B Green and Y P He and Christopher D. Carothers Stephen J. Turner and Michael Jay Yellin and Tibor Keler and Thomas A. Davis and Roger Stupp and John H. Sampson},
  journal={The Lancet. Oncology},
  year={2017},
  volume={18 10},
  pages={
          1373-1385
        }
}
BACKGROUND Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or not the addition of rindopepimut to standard chemotherapy is able to improve survival in patients with EGFRvIII-positive glioblastoma. METHODS In this randomised, double-blind, phase 3 trial, we recruited patients aged 18 years and older with glioblastoma… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas

  • MJ van den Bent, Y Gao, M Kerkhof
  • Neuro Oncol 2015;
  • 2015

IMCT­08 ReACT: Long­term survival from a randomized phase II study of rindopepimut (CDX­110) plus bevacizumab in relapsed glioblastoma

  • DA Reardon, A Desjardins, J Schuster
  • Neuro Oncol 2015;
  • 2015

Similar Papers

Loading similar papers…